6th Annual Cardio Symposium | Washington, D.C. | Sept 29, 2018

Vivian CaoEvent

Join us for our 6th Annual Cardio Symposium on September 29, 2018, in Washington, D.C., held one day prior to the SPS 2018 Annual Meeting. The event will tentatively begin Saturday morning and end in the early evening with a cocktail reception.

Speakers will include;

  • Utility of In-vitro hiPSC-CMs Cardiac Safety Assessments During Early De-risking and Preclinical Candidate Selection: Case-study of Ciluprevir (A Discontinued HCV-NS3/4A Inhibitor)
    • Frederick Sannajust, Ph.D. from Merck, USA
  • Investigating the relevance of human iPS-cardiomyocytes in heart failure drug discovery
    • Ian Moench, Ph.D. from GlaxoSmithKline, USA
  • Application of human iPS cell technology for cardio-oncology 
    • Yasunari Kanda, Ph.D. from NIHS, JAPAN
  • Combined analysis of drug effects by impedance signals and live cell imaging obtained in the same iPSC cardiomyocytes preparation
    • Kohei Sawada, Ph.D. from University of Tokyo, JAPAN
  • Uncovering New Therapeutics in Arrhythmogenic Cardiomyopathy Donor-Reflective Human Induced Pluripotent Stem Cell Derived Cardiomyocytes
    • Farah Sheikh, Ph.D., FCVS, FAHA from UC San Diego, USA
  • Kinase inhibitor-induced toxicity in human iPSC-derived cardiomyocytes: observations from subchronic exposures and heterogeneous cell models
    • Matthew C. White, Ph.D. from Arkansas College of Osteopathic Medicine, USA
  • Case studies: industry’s push towards chronic/structural cardiotoxicity assessment
    • Greg Luerman, Ph.D. from Ncardia, USA
  • The impact of long term electrical pacing on hiPSC CM maturation: A more enhanced model for safety assessment, investigating disease mechanism and cardiac drug discovery
    • Xiaoyu Zhang, Ph.D. from ACEA Biosciences, USA
  • Comparative Assessment of Human iPSC-Derived Cardiomyocytes in Diversity and Disease Modeling
    • T.K. Feaster, Ph.D. from FUJIFILM Cellular Dynamics, USA

ACEA Biosciences’ Cardio Symposium is a forum to promote scientific exchange and collaboration.  Experts from both industry and academia will share their findings on combining human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes, cellular impedance, MEA and other technologies for cardiac safety assessment and cardiovascular disease studies.

Please check back for our list of keynote speakers and full agenda.